Life Cycle Investment Partners Ltd Invests $38.54 Million in argenex SE $ARGX

Life Cycle Investment Partners Ltd purchased a new position in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 45,826 shares of the company’s stock, valued at approximately $38,537,000. Life Cycle Investment Partners Ltd owned 0.07% of argenex as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. M&T Bank Corp lifted its holdings in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the period. Wellington Management Group LLP lifted its holdings in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares during the period. Two Sigma Investments LP lifted its holdings in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after buying an additional 250,278 shares during the period. Woodline Partners LP lifted its holdings in argenex by 320.8% in the third quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after buying an additional 129,205 shares during the period. Finally, Alkeon Capital Management LLC lifted its holdings in argenex by 133.3% in the third quarter. Alkeon Capital Management LLC now owns 175,000 shares of the company’s stock valued at $129,073,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ARGX. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Glj Research upgraded shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Oppenheimer dropped their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Finally, Robert W. Baird boosted their target price on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Price Performance

NASDAQ:ARGX opened at $806.46 on Friday. The firm has a 50-day moving average of $767.17 and a 200-day moving average of $815.87. The company has a market cap of $49.90 billion, a PE ratio of 35.91, a PEG ratio of 1.28 and a beta of 0.46. argenex SE has a one year low of $510.05 and a one year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, equities research analysts expect that argenex SE will post 25.27 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.